Source: NICE
Area: News
The National Institute for Health and Clinical Excellence (NICE) has issued its Final Appraisal Determination (FAD) on ranibizumab for the treatment of diabetic macular oedema (DMO). Within the FAD, ranibizumab is not recommended for the treatment of visual impairment due to DMO. The FAD also states that people currently receiving ranibizumab for the treatment of visual impairment due to diabetic macular oedema should have the option to continue treatment until they and their clinicians consider it appropriate to stop.
The independent Appraisal Committee considered that (Read more...)